Umar Hayat, Ph.D.

Dr. Umar Hayat
Ph.D.

Founder & CEO - Accanito Therapeutics Inc.

Umar Hayat, Ph.D. is a serial entrepreneur and the Founder & CEO of Accanito Therapeutics Inc., a U.S.-based company pioneering mitochondrial-targeted cancer therapies. He also serves as Chairman of Hayat HealthCare Inc., the parent organization of HPC LLC, a pharmaceutical consulting firm, and Trials360 LLC, a global clinical research organization. In addition, he is the Founder and Managing Partner of Revive Pharma US, a company dedicated to repurposing of existing drugs- 505(b)(2) programs.

Dr. Hayat previously served as Chief Technology Officer at Gladius Therapeutics and has also held leadership roles with companies, including Relypsa (acquired by Galenica for US$1.52B), Anacor Pharmaceuticals (acquired by Pfizer for US$5.2B), and Transcept Pharmaceuticals (reverse merger with Paratek valued at US$100M).

Throughout his career, he has played a pivotal role in the development and commercialization of Veltassa® for hyperkalemia (U.S. and EU), Intermezzo® for MOTN insomnia, Kerydin® for onychomycosis, Eucrisa® for atopic dermatitis, and Unafra® (MFDS–South Korea), a non-opioid therapy for post-surgical pain management.

Dr. Hayat earned his Ph.D. in Process Engineering from INP-Toulouse, France, followed by a Post-Doctoral Fellowship at École Polytechnique de Montréal, Canada. He holds an M.Sc. in Chemistry from the Institute of Chemistry, University of the Punjab, Pakistan.

Conference / Speaker Bio

Umar Hayat, Ph.D. is an accomplished biotech entrepreneur and scientific leader whose career spans drug discovery, clinical development, regulatory strategy, and commercialization. As Founder & CEO of Accanito Therapeutics, he is pioneering mitochondrial-targeted cancer therapies. He also serves as Chairman of Hayat HealthCare Inc., guiding both HPC LLC and Trials360 LLC, and is the Founder and Managing Partner of Revive Pharma US, specializing in 505(b)(2) drug repurposing.

Dr. Hayat’s leadership experience includes serving as CTO of Gladius Therapeutics and holding senior roles at Relypsa, Anacor, and Transcept Pharmaceuticals—organizations collectively involved in multi-billion-dollar acquisitions. His scientific and operational contributions have supported the approval and commercialization of several important therapies, including Veltassa®, Intermezzo®, Kerydin®, Eucrisa®, and Unafra®.

He holds a Ph.D. in Process Engineering from INP-Toulouse, a post-doctoral fellowship from École Polytechnique de Montréal, and an M.Sc. in Chemistry from the University of the Punjab.